8th Jul 2016 06:53
LONDON (Alliance News) - Pharmaceutical company Vernalis PLC on Friday said it has completed the comparative bioavailability study on CCP-08, its cough and cold treatment.
The company said the filing of a new drug application for the product in the US remains on track for 2016 following completion of the study.
"We are delighted to report the successful completion of the CCP-08 pivotal bioavailability studies and look forward to further news flow from this programme and others in our prescription long-acting cough cold product pipeline later in 2016," said Chief Executive Ian Garland.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Vernalis PLC